心脏骤停期间肾上腺素药代动力学:一项先导研究
该先导研究纳入9例心脏骤停患者,经外周静脉单次给予1 mg肾上腺素,同时每分钟从颈静脉采血测定血浆浓度。1例未达峰值被排除,余8例共26次测量用于混合效应模型分析,估算浓度下降斜率为-0.259[95%CI(-0.361,-0.157),p<0.001],对应半衰期2.6(1.9,4.4)分钟。作者认为心脏骤停期间肾上腺素消除延长,重复给药可能使血浆水平升高,需进一步更大样本研究确定复苏期间最佳血浆浓度。
要点
- 心脏骤停患者单次外周静脉注射1 mg肾上腺素后,估算半衰期为2.6(1.9,4.4)分钟。
- 混合效应模型显示浓度下降斜率为-0.259[95%CI(-0.361,-0.157),p<0.001]。
- 9例中1例未达峰值浓度被排除,8例共26次测量用于建模。
- 作者认为心脏骤停期间肾上腺素消除延长,重复给药可能致血浆浓度升高。
- 作者指出需进一步更大研究确定复苏期间最佳血浆浓度。
适用人群与场景
- 9例心脏骤停患者;1例因观察期间未达峰值浓度被排除,最终8例纳入分析。
处置流程与药物剂量
- 经外周静脉单次给予1 mg肾上腺素,同时每分钟从颈静脉采血测定血浆浓度。
研究设计与关键结果
- 先导研究:纳入9例心脏骤停患者,1例未达峰值浓度被排除,8例共26次测量用于混合效应模型分析。
- 稳定模型估算浓度下降斜率为-0.259[95%CI(-0.361,-0.157),p<0.001],对应肾上腺素半衰期2.6(1.9,4.4)分钟。
- 作者结论:心脏骤停期间肾上腺素消除延长,重复给药可能导致血浆浓度升高。
证据类型、等级与局限
- 证据类型:先导研究。
- 局限:原文未报告局限性;作者指出需进一步更大研究确定复苏期间最佳血浆浓度。
对床旁实践的改变
- 作者认为心脏骤停期间肾上腺素消除延长,重复给药可能使血浆浓度升高。
- 作者指出需进一步更大研究确定复苏期间最佳血浆浓度。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIM OF THE STUDY: Epinephrine has been recommended for several decades for the treatment of cardiac arrest. However, although this potent medicament has a documented impact on the return of spontaneous circulation, it does not improve long-term survival. Decreased cerebral blood flow, one of the side effects of epinephrine, indicates that the use of this drug is a two-edged sword. Despite clinical recommendations, no study has investigated epinephrine pharmacokinetics in a setting of cardiac arrest. Therefore, in a pilot setting, we measured the plasma concentrations of epinephrine following a single administration.
METHODS: Nine patients with cardiac arrest were included in our study. A single dose of 1 mg epinephrine was administered into a peripheral vein. Simultaneously, blood samples were withdrawn every minute from the jugular vein to determine the plasma concentration. A mixed effects model was used to estimate the T1/2 following the peak concentration.
RESULTS: One patient did not achieve a peak concentration during observation and was hence excluded. The remaining eight patients had 26 measurements suitable for modelling. In a stable model, the decline is estimated to be -0.259 [95% CI (-0.361, -0.157) (p<0.001)]. This implies a half-time for epinephrine of 2.6 (1.9, 4.4) minutes.
CONCLUSION: Our study indicates that elimination of epinephrine during cardiac arrest is prolonged and that repeated doses of epinephrine may lead to increased plasma levels. Further and larger studies are warranted to determine the optimal plasma concentration during resuscitation.
参考来源
- Heradstveit BE, Sunde GA, Asbjørnsen H, et al. Pharmacokinetics of Epinephrine During Cardiac Arrest: A Pilot Study. Resuscitation. 2023. PMID: 39491088. doi:10.1016/j.resuscitation.2023.110025
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。